Form: SCHEDULE 13D

General Statement of Acquisition of Beneficial Ownership






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D




Comment for Type of Reporting Person:
(1) The number of shares in Rows 8, 10 and 11 represents 650,000 shares of common stock, par value $0.001 per share (the "Common Stock"), of Aureus Greenway Holdings Inc. (the "Issuer"), held by The Steven Scopellite 2021 IRR (the "Trust"). Michael Canarick is the trustee of the Trust. As trustee, Michael Canarick exercises voting and investment control over the securities held by the Trust. Steven Scopellite, as grantor of the Trust, may be deemed to share voting and dispositive power over the securities held by the Trust with the trustee, Michael Canarick. Each disclaims beneficial ownership of the securities held by the Trust except to the extent of their respective pecuniary interests. (2) The Trust also holds 10,000,000 shares of Series A Preferred Stock, par value $0.001 per share (the "Preferred Stock"), which are not convertible into common stock. Each share of the Preferred Stock entitles the Trust to votes equal to twenty (20) votes per share of Preferred Stock held. (3) The reported beneficial ownership percentage in Row 13 is based on 14,608,988 shares of Common Stock as reported in the Issuer's Form S-1 filed with the Securities and Exchange Commission on August 4, 2025. (4) The Trust is the sole holder of all issued and outstanding shares of Preferred Stock and after giving effect to the voting rights of such Preferred Stock and the voting rights of the Common Stock beneficially owned by the Trust, the aggregate voting power held by the Trust would be 93.5% of all voting rights of the Issuer's voting securities (based on 214,608,988 aggregate votes).


SCHEDULE 13D




Comment for Type of Reporting Person:
(1) The number of shares in Rows 8, 10 and 11 represents 650,000 shares of Common Stock of the Issuer, held by the Trust. Michael Canarick is the trustee of the Trust. As trustee, Michael Canarick exercises voting and investment control over the securities held by the Trust. Steven Scopellite, as grantor of the Trust, may be deemed to share voting and dispositive power over the securities held by the Trust with the trustee, Michael Canarick. Each disclaims beneficial ownership of the securities held by the Trust except to the extent of their respective pecuniary interests. 2) The Trust also holds 10,000,000 shares of Series A Preferred Stock, which are not convertible into common stock. Each share of the Preferred Stock entitles the Trust to votes equal to twenty (20) votes per share of Preferred Stock held. (3) The reported beneficial ownership percentage in Row 13 is based on 14,608,988 shares of Common Stock as reported in the Issuer's Form S-1 filed with the Securities and Exchange Commission on August 4, 2025. (4) The Trust is the sole holder of all issued and outstanding shares of Preferred Stock and after giving effect to the voting rights of such Preferred Stock and the voting rights of the Common Stock beneficially owned by the Trust, the aggregate voting power held by the Trust would be 93.5% of all voting rights of the Issuer's voting securities (based on 214,608,988 aggregate votes).


SCHEDULE 13D




Comment for Type of Reporting Person:
(1) The number of shares in Rows 8, 10 and 11 represents 650,000 shares of Common Stock of the Issuer, held by the Trust. Michael Canarick is the trustee of the Trust. As trustee, Michael Canarick exercises voting and investment control over the securities held by the Trust. Steven Scopellite, as grantor of the Trust, may be deemed to share voting and dispositive power over the securities held by the Trust with the trustee, Michael Canarick. Each disclaims beneficial ownership of the securities held by the Trust except to the extent of their respective pecuniary interests. (2) The Trust also holds 10,000,000 shares of Series A Preferred Stock, which are not convertible into common stock. Each share of the Preferred Stock entitles the Trust to votes equal to twenty (20) votes per share of Preferred Stock held. (3) The reported beneficial ownership percentage in Row 13 is based on 14,608,988 shares of Common Stock as reported in the Issuer's Form S-1 filed with the Securities and Exchange Commission on August 4, 2025. (4) The Trust is the sole holder of all issued and outstanding shares of Preferred Stock and after giving effect to the voting rights of such Preferred Stock and the voting rights of the Common Stock beneficially owned by the Trust, the aggregate voting power held by the Trust would be 93.5% of all voting rights of the Issuer's voting securities (based on 214,608,988 aggregate votes).


SCHEDULE 13D


 
The Steven Scopellite 2021 IRR
 
Signature:/s/ Michael Canarick
Name/Title:Michael Canarick/Trustee
Date:08/06/2025
 
Michael Canarick
 
Signature:/s/ Michael Canarick
Name/Title:Michael Canarick/Trustee
Date:08/06/2025
 
Steven Scopellite
 
Signature:/s/ Steven Scopellite
Name/Title:Steven Scopellite
Date:08/06/2025